BioXcel Therapeutics, Inc. announced that they completed enrollment in a clinical study on September 13, 2025, evaluating approximately 30 patients, with results expected in Q4 2025. The company raised $37.3 million from July to September 2025 and anticipates sufficient funds to meet operational needs until early 2026.